CTOR - Citius Oncology, Inc.

CTOR - Citius Oncology, Inc.

None

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Citius Oncology Beats Fiscal Q3 EPS

Motley Fool • 1 month ago • score: 0.16

Citius Oncology ( NASDAQ:CTOR ) , a biopharmaceutical company focused on cancer treatments, released results for its fiscal third quarter on August 12, 2025. The most pivotal news was an upside surprise on loss per share, reported at ( $0.08 ) GAAP for the quarter, $0.07 better than analyst ...

Citius Pharmaceuticals Stock Is Soaring Monday: What's Going On? - Citius Pharmaceuticals ( NASDAQ:CTXR )

Benzinga • 3 months ago • score: 0.36

Citius announces a distribution services agreement with Cardinal Health. Cardinal serves as an authorized distributor of record for Citius Oncology, providing specialty pharmaceutical distribution services. Ready to turn the market's comeback into steady cash flow? Grab the top 3 stocks to buy ...

This Deckers Outdoor Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Citius Pharmaceuticals ( NASDAQ:CTXR ) , Citius Oncology ( NASDAQ:CTOR )

Benzinga • 3 months, 3 weeks ago • score: 0.19

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Keybanc analyst Ashley Owens downgraded the rating for Deckers Outdoor Corporation DECK from ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

None

52W High

$6.19

52W Low

$0.55

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

3.01

Valuation

Rich

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

37.59

EV/EBITDA (<8 favorable)

N/A

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

4.55

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

86.83%

Institutions (25–75% balanced)

0.75%

Shares Outstanding

78,371,000

Float

12,299,500

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

-0.39

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-1.08%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

-0.0231

Previous

-0.0258

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025